Resverlogix Corp. (TSE:RVX) – Stock analysts at Zacks Investment Research issued their Q2 2017 earnings per share (EPS) estimates for Resverlogix Corp. in a research note issued on Monday. Zacks Investment Research analyst J. Vandermosten anticipates that the brokerage will earn ($0.06) per share for the quarter. Zacks Investment Research also issued estimates for Resverlogix Corp.’s Q3 2017 earnings at ($0.06) EPS, Q4 2017 earnings at ($0.05) EPS and FY2019 earnings at ($0.22) EPS.

Resverlogix Corp. (TSE:RVX) traded up 3.96% during trading on Thursday, reaching $2.10. The company had a trading volume of 119,394 shares. The company’s market capitalization is $220.94 million. The firm’s 50 day moving average is $1.29 and its 200 day moving average is $1.29. Resverlogix Corp. has a one year low of $1.10 and a one year high of $2.52.

Resverlogix Corp. Company Profile

Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer’s disease and orphan diseases.

Receive News & Ratings for Resverlogix Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix Corp. and related companies with MarketBeat.com's FREE daily email newsletter.